LataMed AI Enters Agreement With DROGUERIAS LALA C.A. to Develop AI and Automation Tools for Pharmaceutical and Laboratory Workflows
CARACAS, VENEZUELA - August 3, 2026 ( NEWMEDIAWIRE ) - LataMed AI Corp. (OTC: LMED) (“LataMed AI” or the “Company”), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, today announced that, through its Venezuelan operating subsidiary LATAMEDAI VE, it has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. Under the agreement, the parties intend to collaborate on the design, development, testing, and evaluation of customized technology intended to support selected workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis. The proposed technology is expected to incorporate software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel ide
Free plan · Plus CA$29 or Pro CA$99/month


